Beth Hecht - 30 Jan 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Reporting relationship: Chief Legal Officer and Corporate Secretary
Issuer ticker: XERS
Reported as of: 30 Jan 2026
Net transaction value: -$1,372,072
SEC form: 4
Accepted by SEC: 02 Feb 2026, 18:11:11 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Hecht

Key filing fact

Beth Hecht filed Form 4 for Xeris Biopharma Holdings, Inc. (XERS) on 02 Feb 2026.

Key facts

This page summarizes Beth Hecht's Form 4 filing for Xeris Biopharma Holdings, Inc. (XERS).
6 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Feb 2026, 18:11.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: -$1,372,072.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001652410 Primary reporting owner

Hecht Beth

Relationship: Chief Legal Officer and Corporate Secretary
Address: C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO
Signature: /s/ Beth Hecht
Signature date: 02 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XERS transaction

Common Stock

Award

Transaction value: $0
Shares: +121,293
Change %: +9.3%
Price: $0.000000
Shares after: 1,429,396
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F1

XERS transaction

Common Stock

Tax liability

Transaction value: $724,040
Shares: -98,375
Change %: -6.9%
Price: $7.36
Shares after: 1,331,021
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F2

XERS transaction

Common Stock

Tax liability

Transaction value: $345,287
Shares: -46,914
Change %: -3.5%
Price: $7.36
Shares after: 1,284,107
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F2

XERS transaction

Common Stock

Tax liability

Transaction value: $178,598
Shares: -24,266
Change %: -1.9%
Price: $7.36
Shares after: 1,259,841
Date: 31 Jan 2026
Ownership: Direct
Footnotes: F2

XERS transaction

Common Stock

Sale

Transaction value: $124,147
Shares: -16,667
Change %: -1.3%
Price: $7.45
Shares after: 1,243,174
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XERS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +162,162
Change %
Price: $0.000000
Shares after: 162,162
Date: 30 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 162,162
Exercise price: $7.36
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.

Footnote F2

Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.

Footnote F3

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

Footnote F4

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

SEC remarks

Chief Legal Officer and Corporate Secretary